The grant proposes a program of basic and clinical research in stem cell transplantation. Preclinical studies in dogs will develop nonmyeloablative conditioning programs for patients with aplastic anemia, who only require immunosuppression for hematopoietic engraftment, and for patients with genetic diseases, e.g. sickle cell disease, where 20-30% donor-type hematopoiesis may suffice to relieve symptoms. The dog model, which allows for in vivo analysis of stem cell function, will be used to define the limits of cord blood transplantation, with emphasis on in vitro expansion that is needed to increase cell yield for transplantation into adults and for gene therapy. Additional studies will focus on improved retroviral delivery systems for gene therapy, to improve upon clinical gene therapy studies already begun in patients with Gaucher's disease. Clinical studies will address ways of increasing the application and efficacy of stem cell transplantation for treating aplastic anemia (AA), myelodysplastic syndromes (MDS), and autoimmune disease, as well as genetic diseases, in conjunction with these projects, in vitro studies of cellular interactions will define how diseased cells in MDS or AA may be capable of suppressing normal hematopoiesis, possibly leading to alternative forms of therapy for these diseases as well as other marrow failure syndromes. Marrow grafts from HLA-identical siblings will be continued with emphasis on developing new regimens for preventing graft rejection and acute GVHD. Efforts to increase the number of patients eligible for transplantation will focus on the use of less well matched family members and of unrelated individuals as donors. As more patients become long-term survivors, long- term follow-up studies have become imperative to understand, treat, and prevent secondary malignancies and chronic GVHD. All of the clinical and laboratory studies are supported by core components which provide sample acquisition and analysis, as well as study design, data processing, and statistical analyses. Other cores deal with the outpatient department and grant administration. The principles derived from the proposed studies will make it possible to provide more effective treatment to a greater number of patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL036444-19
Application #
6043742
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
1985-07-01
Project End
2001-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Thakar, M S; Bonfim, C; Walters, M C et al. (2017) Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplant 52:570-573
Burroughs, Lauri M; Shimamura, Akiko; Talano, Julie-An et al. (2017) Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biol Blood Marrow Transplant 23:1669-1677
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Khera, Nandita; Gooley, Ted; Flowers, Mary E D et al. (2016) Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1319-1323
Karoopongse, Ekapun; Marcondes, A Mario; Yeung, Cecilia et al. (2016) Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biol Blood Marrow Transplant 22:1173-1181
Hoffmeister, P A; Storer, B E; Syrjala, K L et al. (2016) Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. Bone Marrow Transplant 51:153-6
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-1233

Showing the most recent 10 out of 788 publications